Scroll To Top
Health

Incyte stops
development of anti-HIV drug

Incyte stops
development of anti-HIV drug

Drug development halted after reports of pancreatic inflammation.

Support The Advocate
We're asking for your help to continue our newsroom's important reporting. Support LGBTQ+ journalism by contributing today!

Pharmaceutical company Incyte on Monday announced that it has halted developed on its experimental HIV nucleoside reverse transcriptase inhibitor DFC, formerly known as Reverset, because the drug boosted risks for pancreatic inflammation. Researchers noted an increased level of grade 4 hyperlipasemia, a marker of pancreatic inflammation, in the Phase II-b study. Based on the study findings, Incyte announced it has halted enrollment in the clinical trial and will begin working with the Food and Drug Administration to find alternative treatments for the study participants who have drug-resistant virus and few other treatment options. (The Advocate)

The Pride Store HalloweenOut / Advocate Magazine - Jonathan Groff & Wayne Brady

From our Sponsors

Most Popular

Latest Stories

Outtraveler Staff